Prevalence of Acinetobacter baumannii and Candida auris in Patients Receiving Mechanical Ventilation
- PMID: 37824710
- PMCID: PMC10570911
- DOI: 10.1001/jama.2023.21083
Prevalence of Acinetobacter baumannii and Candida auris in Patients Receiving Mechanical Ventilation
Abstract
Importance: To date, only 1 statewide prevalence survey has been performed for Acinetobacter baumannii (2009) in the US, and no statewide prevalence survey has been performed for Candida auris, making the current burden of these emerging pathogens unknown.
Objective: To determine the prevalence of A baumannii and C auris among patients receiving mechanical ventilation in Maryland.
Design, setting, and participants: The Maryland Multi-Drug Resistant Organism Prevention Collaborative performed a statewide cross-sectional point prevalence of patients receiving mechanical ventilation admitted to acute care hospitals (n = 33) and long-term care facilities (n = 18) between March 7, 2023, and June 8, 2023. Surveillance cultures (sputum, perianal, arm/leg, and axilla/groin) were obtained from all patients receiving mechanical ventilation. Sputum, perianal, and arm/leg cultures were tested for A baumannii and antibiotic susceptibility testing was performed. Axilla/groin cultures were tested by polymerase chain reaction for C auris.
Main outcomes and measures: Prevalence of A baumannii, carbapenem-resistant A baumannii (CRAB), and C auris. Prevalence was stratified by type of facility.
Results: All 51 eligible health care facilities (100%) participated in the survey. A total of 482 patients receiving mechanical ventilation were screened for A baumannii and 470 were screened for C auris. Among the 482 patients who had samples collected, 30.7% (148/482) grew A baumannii, 88 of the 148 (59.5%) of these A baumannii were CRAB, and C auris was identified in 31 of 470 (6.6%). Patients in long-term care facilities were more likely to be colonized with A baumannii (relative risk [RR], 7.66 [95% CI, 5.11-11.50], P < .001), CRAB (RR, 5.48 [95% CI, 3.38-8.91], P < .001), and C auris (RR, 1.97 [95% CI, 0.99-3.92], P = .05) compared with patients in acute care hospitals. Nine patients (29.0%) with cultures positive for C auris were previously unreported to the Maryland Department of Health.
Conclusions: A baumannii, carbapenem-resistant A baumannii, and C auris were common among patients receiving mechanical ventilation in both acute care hospitals and long-term care facilities. Both pathogens were significantly more common in long-term care facilities than in acute care hospitals. Patients receiving mechanical ventilation in long-term care facilities are a high-risk population for emerging pathogens, and surveillance and prevention efforts should be targeted to these facilities.
Conflict of interest statement
Figures
Similar articles
-
Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey.Infect Control Hosp Epidemiol. 2012 Sep;33(9):883-8. doi: 10.1086/667376. Epub 2012 Jul 23. Infect Control Hosp Epidemiol. 2012. PMID: 22869261 Free PMC article.
-
The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.Antimicrob Resist Infect Control. 2022 Jan 21;11(1):12. doi: 10.1186/s13756-022-01052-8. Antimicrob Resist Infect Control. 2022. PMID: 35063032 Free PMC article. Review.
-
Surveillance cultures growing carbapenem-Resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study.Clin Infect Dis. 2015 Feb 1;60(3):415-22. doi: 10.1093/cid/ciu847. Epub 2014 Oct 28. Clin Infect Dis. 2015. PMID: 25352586
-
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15. Microb Pathog. 2019. PMID: 30562602
-
A systematic review and meta-analysis for risk factor profiles in patients with resistant Acinetobacter baumannii infection relative to control patients.Int J Risk Saf Med. 2023;34(4):337-355. doi: 10.3233/JRS-220037. Int J Risk Saf Med. 2023. PMID: 37154184 Review.
Cited by
-
A multiplex RPA coupled with CRISPR-Cas12a system for rapid and cost-effective identification of carbapenem-resistant Acinetobacter baumannii.Front Microbiol. 2024 Mar 6;15:1359976. doi: 10.3389/fmicb.2024.1359976. eCollection 2024. Front Microbiol. 2024. PMID: 38516017 Free PMC article.
References
-
- CDC . Antibiotic resistance threats in the United States, 2019. Revised December 2019. Accessed September 30, 2023. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re...
-
- Global research agenda for antimicrobial resistance in human health. WHO; June 2023. Accessed July 20, 2023. https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/a...
-
- Maryland Department of Health, University of Maryland School of Medicine . Acinetobacter baumannii and Candida auris Collaborative. Accessed July 25, 2023. https://sites.google.com/view/maryland-acinetobacter-c-auris/home
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
